Recent News Stay up to date on the latest news about Abpro, including press releases and upcoming publications. News Press Releases Publications Press Releases FEB 2, 2021Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19Read More → DEC 16, 2020Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19Read More → NOV 25, 2020Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease LeadersRead More → NOV 16, 2020Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19Read More → OCT 20, 2020Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19Read More → MAR 3, 2020Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian MarketsRead More → FEB 28, 2019Abpro and NJCTTQ Enter Into Partnership For Development of Multiple Novel Bispecific AntibodiesRead More → NOV 29, 2016Medimmune and Abpro Enter into A Collaborative Agreement For a Novel Bispecific AntibodyRead More → OCT 13, 2016GEN Roundup: Immunoassays: Life Science Critical ToolsRead More → MAY 20, 2016Abpro Announces Agreements with Two Boston HospitalsRead More → APR 25, 2016Abpro Announces Investment and Partnership with Essex BioRead More → OCT 10, 2014Abpro Co-Founder Eugene Chan Wins Nokia Sensing XChallengeRead More → Publications November 6, 2019Abpro's TetraBi Platform for T-cell Engaging Antibodies targeting Claudin 18.2-expressing cancers Published for the 2019 SITC meetingRead More → MAY 16, 2019Abpro's TetraBi Platform for T-cell Engaging Antibodies Published for the 2019 ASCO MeetingRead More →
